Skip to search formSkip to main contentSkip to account menu

mafosfamide

Known as: 2-((2-(bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorin-4-yl)thio)ethanesulfonic acid P-oxide 
A synthetic oxazaphosphorine derivative with antineoplastic properties. Mafosfamide alkylates DNA, forming DNA cross-links and inhibiting DNA… 
National Institutes of Health

Related topics

Related topics

6 relations

Broader (3)

Antineoplastic AgentsCyclophosphamideImmunologic Adjuvants
NCIt Antineoplastic Agent Terminologyanalogs & derivatives

Narrower (1)

z 7557

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Chemical characterization of ASTA Z 7557 (INN mafosfamide, CIS-4-sulfoethylthio-cyclophosphamide), a stable derivative of 4-hydroxy-cyclophosphamide
SummaryThe primary metabolite of cyclophosphamide (CP, 1), i.e. 4-hydroxy-CP 2, has high pharmacological activity, but it is a… 
2004
2004
Phase-I study of mafosfamide-cyclohexylamine (ASTA-Z-7557, NSC 345 842) and limited phase-I data on mafosfamide-lysine
SummaryMafosfamide-cyclohexylamine is a new oxazaphosphorine derivative. It was chosen for phase-I clinical testing because of an… 
2004
2004
Comparative in vitro cytotoxicity of cyclophosphamide, its major active metabolites and the new oxazaphosphorine ASTA Z 7557 (INN mafosfamide)
SummaryCyclophosphamide (CPA), the most commonly used alkylating agent in the treatment of a wide variety of hematologic and… 
2000
2000
Ex vivo assessment of drug response by differential staining cytotoxicity (DiSC) assay suggests a biological basis for equality of chemotherapy irrespective of age for patients with chronic…
With a mean age at diagnosis for chronic lymphocytic leukaemia (CLL) of 65 years, development of optimal therapeutic regimens has… 
2000
2000
Purging of G-CSF-mobilized peripheral autografts in acute leukemia with mafosfamide and amifostine to protect normal progenitor cells
In the present study the in vitro growth of CFU-GM from PBPC of patients with AML (n = 11), purged with mafosfamide alone or a… 
1995
1995
Characterization of late and early hematopoietic progenitor/stem cell sensitivity to mafosfamide.
The preservation of the hematopoietic value of the graft is essential in the context of bone marrow purging for autologous… 
1995
1995
Autologous bone marrow transplantation as consolidation therapy may prolong remission in newly diagnosed high-risk follicular lymphoma: a pilot study of 34 cases.
We evaluated early intensification followed by autologous bone marrow transplantation (ABMT) using marrow purged by mafosfamide… 
1992
1992
Use of recombinant human granulocyte-macrophage colony-stimulating factor in patients with lymphoid malignancies transplanted with unpurged or adjusted-dose mafosfamide-purged autologous marrow.
The neutropenia-related morbidity and mortality occurring after autologous bone marrow transplantation (ABMT) is increased by… 
Highly Cited
1989
Highly Cited
1989
Hydrogen ion-mediated enhancement of cytotoxicity of bis-chloroethylating drugs in rat mammary carcinoma cells in vitro.
Aerobic glycolysis, a metabolic characteristic of malignant cells, can be exploited to increase the concentration of lactic acid… 
1987
1987
Preclinical and early clinical trial with mafosfamide as immune modulator.
Low doses of cyclophosphamide (CPA) modulate immune responses and induce complete tumor regression and cures in mice. The… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)